Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Sabirnetug · ACU-193

Monoclonal antibody · developed by Acumen Pharmaceuticals

Phase 2 Most advanced trial

ABOS Developer

3 Registered trials

What is Sabirnetug?

Sabirnetug is an antibody administered by intravenous infusion being studied in Alzheimer disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ACU-193
Drug type: Monoclonal antibody
Therapy area: Neurology
Developer: Acumen Pharmaceuticals (ABOS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 2U1A25MKP9

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06335173	Phase 2	Alzheimer Disease	Active not recruiting	ABOS
NCT06511570	Phase 1	Alzheimer Disease	Completed	ABOS
NCT04931459	Phase 1	Alzheimer Disease	Completed	ABOS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer Disease

Sources

ClinicalTrials.gov NCT06511570

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABOS page.

Follow ABOS, the company behind Sabirnetug

See ABOS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABOS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z